BioCentury
ARTICLE | Clinical News

SPK-CHM: Phase I/II started

February 2, 2015 8:00 AM UTC

Spark began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate 2 single doses of subretinal SPK-CHM in up to 10 males with mutations in the CHM gene. Choroideremia is a rare inherited d...